Opioid Addiction Treatment ECHO
For Providers and Primary Care Teams
Medication Treatment for Opioid Use Disorder

Developer: Joe Merrill, MD, University of Washington, Charles Morgan MD, and Anne Griepp MD, Western New York Collaborative And Miriam Komaromy, MD, University of New Mexico Reviewer/Editor: Miriam Komaromy, MD, The ECHO Institute™ Presenter: Gabriela Williams, PharmD, BCPS, BCPP, Eskenazi Health
Disclosures

Joe Merrill, Charles Morgan, and Ann Griep, Miriam Komaromy and Gabriela Williams have nothing to disclose.
Medications for Opioid Use Disorder

• Buprenorphine (sublingual and implantable)
• Naltrexone (oral and extended release injectable)
• Methadone

“Detox” has no long-term effect on outcomes; it is medication maintenance that saves lives and reduces relapse
Tolerance & Physical Dependence

Medication Assisted Therapy

Acute Use

Chronic Use

Alford, Boston University, 2012
Pharmacotherapy for Opioid Addiction: Methadone

• Most effective
  • survival, treatment retention, employment
  • illicit opioid use, hepatitis and HIV infections, criminal activity

• Highly regulated, dispensed at Opioid Treatment Programs (OTP)
  • Supervised daily dosing with take-home doses if stable
  • Counseling, urine testing
  • Psychiatric, medical services often not provided
  • Illegal to prescribe methadone for addiction in general practice

• Cost-effective
  • Every dollar invested generates $4-5 in savings
Pharmacotherapy for Opioid Addiction: Methadone

Daily, observed dosing
- Full opioid agonist
- Onset within 30-60 minutes
- Long-acting: Daily dosing effective for addiction
- Dose 20-40 mg for acute withdrawal
- >80 mg for craving and “blockade”
- To evaluate stability, ask about take-home doses
- **Multiple** medication interactions

Advise staying in treatment until social, medical, psychiatric, legal, and family issues are stable.
- “Detox” therapy has no long-term effect on outcomes
- Longer duration, higher dose treatment most effective
- For some patients methadone therapy should be lifelong, as risk of relapse is high after cessation
METHADONE...

Highly effective

**FACTS**

- One of the WHO list of 100 essential meds that should be available worldwide
- Decreases risk of HIV and Hepatitis C infection
- Reduces relapse

**MYTHS**

- Still addicted
- Can’t nurse your baby
- Always sedated
- Gets in the bones
- Can’t drive
- Bad for your baby
- Rots your teeth
Pharmacotherapy for Opioid Addiction: Buprenorphine

  • Made office-based addiction treatment by physicians legal
  • Must complete 8-hour training and obtain federal waiver
• 2002: Suboxone (buprenorphine/naloxone) FDA approved
  • Outcomes much superior to psychosocial treatment alone
  • Longer treatment duration is more effective
• Compared to methadone:
  • Similar abstinence from illicit opioids and decreased craving
  • Lower retention in treatment
  • Can be prescribed in general practice, lowering barriers to treatment
Pharmacotherapy for Opioid Addiction: Buprenorphine

• Partial opioid agonist, so safer than methadone
• High mu receptor affinity, so blocks other opioids
• Formulated with naloxone - abuse deterrent
• Sublingual dosing and newer implant (Probuphine)
• Can precipitate withdrawal in tolerant patients
• Requires induction after patient enters mild-moderate withdrawal
• Home induction appears to be safe and effective, widely adopted
• Induction from methadone more difficult (taper to ~30 mg)
• Implant approved for stable patients on ≤8 mg buprenorphine
Why is Overdose Potential Low with Buprenorphine?

- **Opioid Effects**
- **Log dose**
- **Respiratory suppression, death**
- **Partial Agonist: Buprenorphine**
- **Antagonist: Naltrexone**
- **Agonist: Methadone, Heroin, etc.**
Trial of Buprenorphine

- 40 people addicted to heroin
- Buprenorphine 16 mg/day vs taper + placebo
- All received individual counseling + therapy groups
- Followed for 1 year

<table>
<thead>
<tr>
<th></th>
<th>Buprenorphine 16 mg per day</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retained at 1 yr</td>
<td>75%</td>
<td>0</td>
</tr>
<tr>
<td>% died</td>
<td>0</td>
<td>20%</td>
</tr>
</tbody>
</table>

Kakko et al, Lancet 2003
Buprenorphine in Primary Care

• Not widely used in primary care
• Most prescribers treat few patients, so poor access
• Barriers in primary care include:
  • Urgency of scheduling
  • Induction visit and frequent early follow up (consider home induction)
  • Urine testing and prescription logistics
  • Linkages to psychosocial services
  • Difficult decisions about when to stop or refer
• Some physicians restrict prescribing to patients who were already in their own practice
Advantages of buprenorphine in primary care:
- Setting built for chronic disease management
- Reduces the stigma of addiction treatment
- Reduced contact with active drug users
- Facilitates management of mental health and medical co-morbidities and preventive care
- Important tool when problems arise during chronic opioid therapy
- Public health benefit: increases local access to lifesaving care

Highly gratifying form of treatment!
Naltrexone

- Opioid antagonist that blocks other opioids
- Does not lead to physical dependence, or to withdrawal when stopped
- Causes acute withdrawal in opioid-dependent patients
- Can be used in office-based settings without added training
- Effective in alcohol use disorder treatment
- Two formulations available:
  - Oral ReVia 50 mg PO daily
  - Injectable Vivitrol 360 mg IM monthly
Naltrexone for Opioid Use Disorder

- Requires opioid abstinence prior to initiation, a major barrier since most treatment-seeking patients are actively using opioids
- Difficult to compare with methadone or buprenorphine (trial underway)
- Russian studies show benefit in population where opioid substitution therapy is not available
- Mixed results in US populations (Cochrane reviews)
- Recent study (Lee, NEJM) in criminal justice population showed short term reduction in opioid relapse compared with “usual care” (not buprenorphine or methadone), and reduction in overdose compared with no medication
Overdose Prevention

• Naloxone ("Narcan") reverses opioid overdose
• Overdose education and naloxone is an effective harm reduction strategy
• For those at high risk of overdose and their friends or family
• Populations: syringe exchange, exit from jail, in drug treatment, high risk prescribed opioids
• Prescribe to Prevent educational modules: http://www.opioidprescribing.com/naloxone_module_1-landing
Summary: Medications for Opioid Use Disorder

- Prescription opioid and heroin epidemics are major public health problems
- Medications are an essential component of evidence-based treatment
- Methadone and buprenorphine are the most effective pharmacotherapies for opioid use disorder
- Naltrexone can also be used, but only in patients who are not currently physically dependent on opioids
- Primary care teams can play an important role in treatment of opioid use disorders and prevention of overdose
References:

Unobserved "home" induction onto buprenorphine.
Lee JD¹, Vocci F, Fiellin DA

Cunningham CO, Giovanniello A, Li X, Kunins HV, Roose RJ, Sohler NL.

J Addict Med. 2011 Dec;5(4):254-63. doi:

Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.
Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH.
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Mattick RP, Breen C, Kimber J, Davoli M.
Cochrane Database Syst Rev. 2014


Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.
Amato L, Minozzi S, Davoli M, Vecchi S.

1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.
Kakko J¹, Svanborg KD, Kreek MJ, Heilig M.

Schwartz RP¹, Gryczynski J, O'Grady KE, Sharfstein JM, Warren G, Olsen Y, Mitchell SG, Jaffe JH
Sustained-release naltrexone for opioid dependence.
Lobmaier P1, Kornør H, Kunøe N, Bjørndal A

Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
Lee JD1, Friedmann PD1, Kinlock TW1, Nunes EV1, Boney TY1, Hoskinson RA Jr1, Wilson D1, McDonald R1, Rotrosen J1, Gourevitch MN1, Gordon M1, Fishman M1, Chen DT1, Bonnie RJ1, Cornish JW1, Murphy SM1, O'Brien CP1

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E1, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL.

Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
LaBelle CT, Han SC, Bergeron A, Samet JH.
Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.
Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH.


Vermont responds to its opioid crisis.
Simpatico TA

Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists.
Lim JK, Bratberg JP, Davis CS, Green TC, Walley AY